WASHINGTON, May 7, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (VNDA) today announced financial and operational results for the first quarter ended March 31, 2025. "Vanda has entered a new growth ...

HC Wainwright initiated coverage on Vanda Pharmaceuticals, Inc. (NASDAQ:VNDA), a commercial-stage biopharmaceutical firm primarily focusing on neurological and neuropsychiatry disorders. HC Wainwright ...

WASHINGTON, April 20, 2015 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced that it has named Tom Gibbs as Senior Vice President, Chief Commercial Officer of the ...

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Q2 2025 Earnings Call Transcript July 31, 2025 Vanda Pharmaceuticals Inc. misses on earnings expectations. Reported EPS is $-0.46 EPS, expectations were $-0.34 ...

Earnings call Vanda delivered Q3 2025 revenue of $56.3M, up 18% YoY and 7% QoQ, led by a 31% YoY surge in Fanapt sales following its bipolar I indication launch. Despite strong top-line growth, net ...

A series of increasing buyout offers has failed to convince Vanda's board of directors that the company should sell itself. After receiving "unsolicited" buyout proposals from Michigan-based CDMO ...

Vanda Pharmaceuticals specializes in developing and commercializing therapies for neurological and rare disorders. Its main products include Fanapt®, an antipsychotic for schizophrenia and bipolar I ...

WASHINGTON, May 5, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (VNDA) today announced that the U.S. Food and Drug Administration (FDA) informed Vanda that the New Drug Application (NDA) for ...

Vanda reported strong phase 2 results for a candidate that could be used with GLP-1 drugs. However, this medicine's potential target market appears small and may shrink further. Even with some ...

WASHINGTON - Vanda Pharmaceuticals Inc. (NASDAQ: VNDA), currently valued at $273.5 million, has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for Bysanti™, a ...